Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Arrieta O, Vega-González MT, López-Macías D, Martínez-Hernández JN, Bacon-Fonseca L, Macedo-Pérez EO, Ramírez-Tirado LA, Flores-Estrada D, de la Garza-Salazar J. Arrieta O, et al. Among authors: macedo perez eo. Lung Cancer. 2015 Jun;88(3):282-8. doi: 10.1016/j.lungcan.2015.03.019. Epub 2015 Mar 28. Lung Cancer. 2015. PMID: 25882778 Clinical Trial.
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
Arrieta O, De la Torre-Vallejo M, López-Macías D, Orta D, Turcott J, Macedo-Pérez EO, Sánchez-Lara K, Ramírez-Tirado LA, Baracos VE. Arrieta O, et al. Among authors: macedo perez eo. Oncologist. 2015 Aug;20(8):967-74. doi: 10.1634/theoncologist.2015-0058. Epub 2015 Jul 14. Oncologist. 2015. PMID: 26173839 Free PMC article. Clinical Trial.
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO, Morales-Oyarvide V, Mendoza-García VO, Dorantes-Gallareta Y, Flores-Estrada D, Arrieta O. Macedo-Pérez EO, et al. Cancer Chemother Pharmacol. 2014 Oct;74(4):681-90. doi: 10.1007/s00280-014-2522-9. Epub 2014 Jul 25. Cancer Chemother Pharmacol. 2014. PMID: 25059320
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Arrieta O, López-Macías D, Mendoza-García VO, Bacon-Fonseca L, Muñoz-Montaño W, Macedo-Pérez EO, Muñiz-Hernández S, Blake-Cerda M, Corona-Cruz JF. Arrieta O, et al. Cancer Chemother Pharmacol. 2014 May;73(5):975-82. doi: 10.1007/s00280-014-2429-5. Epub 2014 Apr 1. Cancer Chemother Pharmacol. 2014. PMID: 24687408 Clinical Trial.
[National consensus of diagnosis and treatment of non-small cell lung cancer].
Arrieta O, Guzmán-de Alba E, Alba-López LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, Allende-Pérez SR, Alvarado-Aguilar S, Araujo-Navarrete ME, Argote-Greene LM, Aquino-Mendoza CA, Astorga-Ramos AM, Austudillo-de la Vega H, Avilés-Salas A, Barajas-Figueroa LJ, Barroso-Quiroga N, Blake-Cerda M, Cabrera-Galeana PA, Calderillo-Ruíz G, Campos-Parra AD, Cano-Valdez AM, Capdeville-García D, Castillo-Ortega G, Casillas-Suárez C, Castillo-González P, Corona-Cruz JF, Correa-Acevedo ME, Cortez-Ramírez SS, de la Cruz-Vargas JA, de la Garza-Salazar JG, de la Mata-Moya MD, Domínguez-Flores ME, Domínguez-Malagón HR, Domínguez-Parra LM, Domínguez-Peregrina A, Durán-Alcocer J, Enríquez-Aceves MI, Elizondo-Ríos A, Escobedo-Sánchez MD, de Villafranca PE, Flores-Cantisani A, Flores-Gutiérrez JP, Franco-Marina F, Franco-González EE, Franco-Topete RA, Fuentes-de la Peña H, Galicia-Amor S, Gallardo-Rincón D, Gamboa-Domínguez A, García-Andreu J, García-Cuéllar CM, García-Sancho-Figueroa MC, García-Torrentera R, Gerson-Cwilich R, Gómez-González A, Green-Schneeweiss L, Guillén-Núñez Mdel R, Gutiérrez-Velázquez H, Ibarra-Pérez C, Jiménez-Fuentes E, Juárez-Sánchez P, Juárez-Ramiro A, Kell… See abstract for full author list ➔ Arrieta O, et al. Rev Invest Clin. 2013 Mar;65 Suppl 1:S5-84. Rev Invest Clin. 2013. PMID: 24459776 Spanish.
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Arrieta O, Cruz-Rico G, Soto-Perez-de-Celis E, Ramírez-Tirado LA, Caballe-Perez E, Martínez-Hernández JN, Martinez-Alvarez I, Soca-Chafre G, Macedo-Pérez EO, Astudillo-de la Vega H. Arrieta O, et al. Among authors: macedo perez eo. Target Oncol. 2016 Oct;11(5):619-629. doi: 10.1007/s11523-016-0425-x. Target Oncol. 2016. PMID: 27033062 Clinical Trial.
Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O, Villarreal-Garza C, Martínez-Barrera L, Morales M, Dorantes-Gallareta Y, Peña-Curiel O, Contreras-Reyes S, Macedo-Pérez EO, Alatorre-Alexander J. Arrieta O, et al. BMC Cancer. 2013 May 22;13:254. doi: 10.1186/1471-2407-13-254. BMC Cancer. 2013. PMID: 23697613 Free PMC article.
15 results